Sirtex Medical announces new SIR-Spheres(R) DOORwaY-90 Study: The first prospective multicenter U.S.-based trial for registration as first-line treatment for hepatocellular carcinoma
WOBURN, Mass., March 22, 2021 -- (Healthcare Sales & Marketing Network) -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced full FDA approval of the DOORwaY90 Study, a trial evaluating the safety an... Devices, Oncology Sirtex Medical, SIR-Spheres, Y-90 resin microspheres, hepatocellular carcinoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Therapy | Carcinoma | Hepatocellular Carcinoma | Liver | Liver Cancer | Marketing | Pharmaceuticals | Study | Urology & Nephrology